Members

FMODD Chair
Kaori Fukuzawa,
Osaka University
The FMO Drug Design Consortium (FMODD) was founded at the end of 2014 by volunteers from industry, academia, and government wishing to promote the fragment molecular orbital (FMO) method as a practical tool for in silico drug design. The FMO method, a theoretical method proposed by Professor Kazuo Kitaura in 1999, enables precise evaluation of the interaction between biomolecules, such as proteins and polynucleotides, and drug candidate compounds at the electronic level by ab initio quantum chemical calculation. In FMODD, we are applying FMO to practical drug design while also developing new FMO-based drug design technology. Concurrently, we are constructing an FMO database (FMODB) to archive enormous calculation data obtained with several supercomputers. These unprecedented “FMO drug design” initiatives are now expanding even to the development of new force fields and to the combination with AI, and are expected to lead not only to the design of new drugs but also to clarification of biological phenomena. We are aiming to establish a new drug design platform open to the world from Japan.

FMODD Vice chair
Teruki Honma, RIKEN Center for Biosystems Dynamics Research

FMODD Vice chair
Tomonaga Ozawa
Kissei Pharmaceuticals Co., Ltd.

: Shigenori Tanaka, Kobe University; Midori Kamimura, Quantum-Structural Life Science Laboratories

: Chiduru Watanabe, RIKEN; Koichiro Kato, Kyushu University; Daisuke Takaya, Osaka University; Tatsuya Ohyama, Konan University; Koji Okuwaki, JSOL CORPORATION; Yoshiharu Mori, Kobe University; Yuto Komeiji, AIST

: Takagi Laboratoy, Osaka University Graduate school of Pharamaceutial Sciences; Structural Biology Kinoshita Group, Ohsaka Prefectural University; Yagi Laboratoy, Okayama University of Science; Laboratory of computational chemistry for life science, Kagoshima University Graduate School of Science and Engineering; Computational Life Science Laboratory, Kindai University; Kumamoto University; Kyushu University; Tanaka Laboratory, Kobe University Graduate School of System Informatics; Konan Univeristy; National Institute of Health Sciences; National Cerebral Cardiovascular Center; Juntendo University School of Medicine; Pharmaceutical Chemistry Laboratory, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University; National Institue of Advanced Industrial Science and Technology (AIST); Faculty of Pharmaceutical Sciences, Setsunan University; Chiba University; Tokai University; Quatum Biology Laboratory, Toyohashi Univeristy of Technology; Niigata University; Yamanaka Laboratory, College of Science and Technology, Nihon University; Department of Physical Chemistry, Hoshi University; Yokohama City University; Laboratory for Structure-Based Molecular Design, RIKEN Center for Biosystems Dynamics Research; Quantum-Structural Life Science Laboratories

: With Metis Co., Ltd.; Kaken Pharmaceutical Co.,Ltd.; Kaneka Corporation; Carna Biosciences, Inc.; Kissei Pharmaceutical Co., Ltd.; Konan Chemical Industry Co., Ltd.; Kowa Company, Ltd.; CONFLEX Corporation; Science & Technology Systems Inc.; Scorpion Tech LLC.; Taisho Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Corporation; Teijin Pharma Ltd.; NARD institute,Ltd.; Nippon Shinyaku Co. Ltd.; Fujifilm Corporation; Mizuho Research & Technologies, Ltd.; MOLSIS Inc.; Evotec (UK) Ltd.; Meiji Seika Pharma Co. Ltd.; Veritas In Silico Inc.

Yukihiro Eguchi, Systems PharmSciences Research Organization

Chisachi Kato, Institute of Industrial Science, University of Tokyo

Kazuo Kitaura, Fukui Institute for Fundamental Chemistry, Kyoto University

Tsuneaki Sakata, Co-creation Bureau, Osaka University

Fumitoshi Sato, Institute of Industrial Science, University of Tokyo

Isao Nakanishi, Kindai University

Takatsugu Hirokawa, University of Tsukuba

Kenji Mizuguchi, National Institute of Biomedical Innovation, Health and Nutrition

Dmitri G. Fedorov, AIST